金佰利-克拉克公司正在周五举行投资者电话会议，以备可能的债券发行，因为其对泰诺生产商Kenvue Inc.的待收购交易即将完成。
Corp. is holding investor calls on Friday ahead of a possible bond sale, as the closing of its pending acquisition of Tylenol maker Kenvue Inc. nears.
根据一位知情人士透露，这些电话会议由摩根大通公司协调，该人士因细节属私人信息而要求匿名。该人士补充称，潜在的五档债券交易可能包括两年到十年期限的债券。
The calls are being coordinated by JPMorgan Chase & Co., according to a person with knowledge of the matter, who asked not to be identified because the details are private. The potential five-tranche deal may include bonds maturing in two to 10 years, the person added.
摩根大通公司为金佰利-克拉克计划中的现金和股票收购Kenvue提供了77亿美元的桥梁融资，该收购预计将在今年年底前完成。桥梁资金通常会被债券发行所得替代。目前该收购价值约360亿美元，其中包括67亿美元的现金，部分将来自新债券发行。
JPMorgan Chase & Co. provided $7.7 billion in bridge financing to help fund Kimberly-Clark’s planned cash-and-stock purchase of Kenvue, which is expected to be completed by the end of this year. Bridge funds are often replaced with proceeds from bond sales. The takeover is currently worth about $36 billion, including $6.7 billion of cash that would in part come from new debt sales.
金佰利-克拉克的债券发行将进入近期动荡的市场。众多公司因国债收益率因通胀数据强于预期而剧烈波动以及对人工智能交易的担忧，推迟了高评级债券的发行。
A bond sale by Kimberly-Clark would enter what’s been a turbulent market in recent days. Numerous companies have held off on bringing high-grade bond sales as Treasury yields swung sharply on stronger-than-expected inflation data and worries about the artificial-intelligence trade.
金佰利-克拉克的第三季度财报将于11月5日发布。公司通常不会在披露财报前大约两周内发行债券。
Kimberly-Clark’s third-quarter report is due on Nov. 5. Firms typically don’t issue bonds in the roughly two-week period before disclosing results.
去年11月交易披露时，金佰利-克拉克（克林克斯所有者）表示，此次合并将创造一家年收入达320亿美元的公司，使其能够超过联合利华，成为仅次于宝洁公司的全球第二大健康与保健产品卖家。
At the time of the deal’s unveiling last November, the Kleenex owner said the combination would create a company with $32 billion in revenue and allow it to surpass Unilever Plc to become the second-biggest seller of health and wellness products after Procter & Gamble Co.
Kenvue的产品组合还包括妥思润肤露、李施德林漱口水、本那黛过敏药和创可贴伤口护理产品。
Kenvue’s portfolio also includes Neutrogena lotion, Listerine mouthwash, Benadryl allergy medicine and Band-Aid wound care products.